Relay Therapeutics, Inc. financial data

Symbol
RLAY on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2053% % 17%
Debt-to-equity 10% % -17%
Return On Equity -43% % 2.7%
Return On Assets -39% % 0.83%
Operating Margin -1972% % 47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 178,725,809 shares 4.2%
Common Stock, Shares, Outstanding 173,868,949 shares 3.6%
Entity Public Float $585,500,000 USD -32%
Common Stock, Value, Issued $168,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 171,586,558 shares 20%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $15,355,000 USD 53%
Revenue from Contract with Customer, Excluding Assessed Tax $15,355,000 USD 53%
General and Administrative Expense $56,710,000 USD -26%
Operating Income (Loss) $302,738,000 USD 19%
Net Income (Loss) Attributable to Parent $276,479,000 USD 18%
Earnings Per Share, Basic -1.61 USD/shares 32%
Earnings Per Share, Diluted -1.61 USD/shares 32%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $84,018,000 USD -32%
Other Assets, Current $5,974,000 USD -43%
Assets, Current $578,279,000 USD -29%
Property, Plant and Equipment, Net $1,726,000 USD -71%
Operating Lease, Right-of-Use Asset $39,990,000 USD -23%
Assets $621,331,000 USD -29%
Accounts Payable, Current $7,705,000 USD -45%
Accrued Liabilities, Current $13,645,000 USD -36%
Liabilities, Current $25,578,000 USD -50%
Operating Lease, Liability, Noncurrent $28,693,000 USD -33%
Liabilities $54,271,000 USD -42%
Accumulated Other Comprehensive Income (Loss), Net of Tax $733,000 USD
Retained Earnings (Accumulated Deficit) $2,014,769,000 USD -16%
Stockholders' Equity Attributable to Parent $567,060,000 USD -27%
Liabilities and Equity $621,331,000 USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $73,210,000 USD -45%
Net Cash Provided by (Used in) Investing Activities $42,465,000 USD 303%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 173,868,949 shares 3.6%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $30,745,000 USD -437%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85,354,000 USD -32%
Deferred Tax Assets, Valuation Allowance $480,517,000 USD 11%
Deferred Tax Assets, Gross $491,341,000 USD 10%
Depreciation $1,208,000 USD -13%
Payments to Acquire Property, Plant, and Equipment $384,000 USD -78%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $274,755,000 USD 19%
Property, Plant and Equipment, Gross $23,273,000 USD -33%
Operating Lease, Liability, Current $3,765,000 USD -34%
Deferred Tax Assets, Operating Loss Carryforwards $235,130,000 USD 41%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $2,580,928,000 USD 2.5%
Deferred Tax Assets, Net of Valuation Allowance $10,824,000 USD -22%
Share-based Payment Arrangement, Expense $94,139,000 USD 9.4%